NCT05267327View on ClinicalTrials.gov

A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast

Not yet recruitingOBSERVATIONAL

Enrollment

1,500

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

May 31, 2026

Conditions

The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks

Interventions

OTHER

Verzenios

Study drug is Verzenios, it is an observational study.

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT05267327 - A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast | Biotech Hunter | Biotech Hunter